As of 2025-07-14, the Intrinsic Value of Nuvo Pharmaceuticals Inc (MRV.TO) is 13.11 CAD. This MRV.TO valuation is based on the model Discounted Cash Flows (Growth Exit 10Y). With the current market price of 1.35 CAD, the upside of Nuvo Pharmaceuticals Inc is 871.10%.
The range of the Intrinsic Value is 4.69 - 93.94 CAD
Based on its market price of 1.35 CAD and our intrinsic valuation, Nuvo Pharmaceuticals Inc (MRV.TO) is undervalued by 871.10%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (5.54) - 1.31 | (4.90) | -462.9% |
| DCF (Growth 10y) | 4.69 - 93.94 | 13.11 | 871.1% |
| DCF (EBITDA 5y) | (3.53) - (1.72) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (0.06) - 3.40 | 1.12 | -17.4% |
| Fair Value | 6.65 - 6.65 | 6.65 | 392.82% |
| P/E | 1.33 - 1.33 | 1.33 | -1.4% |
| EV/EBITDA | 1.61 - 20.21 | 10.16 | 652.3% |
| EPV | 35.65 - 37.82 | 36.73 | 2621.1% |
| DDM - Stable | 16.78 - 348.62 | 182.70 | 13433.5% |
| DDM - Multi | (40.13) - (659.30) | (76.20) | -5744.7% |
| Market Cap (mil) | 15.39 |
| Beta | 0.83 |
| Outstanding shares (mil) | 11.40 |
| Enterprise Value (mil) | 83.45 |
| Market risk premium | 5.10% |
| Cost of Equity | 6.95% |
| Cost of Debt | 5.37% |
| WACC | 5.40% |